

# CLINUVEL

## ASX ANNOUNCEMENT

Melbourne, Australia, 6 September 2024

ASX: CUV | Börse Frankfurt: UR9 | ADR Level 1: CLVLY

## CLINUVEL Board Renewal, Expansion

Brenda Shanahan to retire after 17 years' service,  
three new Non-Executive Directors appointed

CLINUVEL today announced that Non-Executive Director Brenda Shanahan has advised the Board that she will retire as a Director of the Company at the conclusion of the next Annual General Meeting, with three new Non-Executive Directors appointed today.

### Retirement of Mrs Brenda Shanahan

Mrs Shanahan joined CLINUVEL's Board in 2007 and was the Non-Executive Chair of the Board from late 2007 until July 2010. She also Chaired the Audit & Risk Committee.

*"On behalf of the Board, I wish to sincerely thank Mrs Shanahan for her extensive contributions to our Board and to CLINUVEL over more than 17 years," CLINUVEL's Chair, Prof Jeffrey Rosenfeld said. "Her astute business acumen and experience have proved invaluable to the Board's deliberations."*

*"Significantly, after 17 years of Board membership, with a keen eye on success and always having looked at our undertakings from shareholders' perspective, we regretfully see Brenda Shanahan step down from the Board at this year's Annual General Meeting," CLINUVEL's Managing Director, Dr Philippe Wolgen said. "Brenda is a perceptive professional, the prima inter pares in Australian public markets, a real pioneer for women on public Boards, and a first female stockbroker in Australia. Her contributions during decisive moments have been numerous, her drive to build a profitable entity has been remarkable, embracing business challenges. We thank Brenda for her guidance."*

### Appointment of new Non-Executive Directors

CLINUVEL has appointed three Non-Executive Directors, following an extensive search process. Mr Matthew Pringle, Mr Guy van Dievoet and Dr Pearl Grimes have been appointed as Non-Executive Directors with effect from 6 September 2024 and will stand for election at CLINUVEL's Annual General Meeting on 16 October 2024.

Mr Pringle has extensive experience in corporate finance, audit and assurance, governance and strategy, including over 25 years' experience as a Partner at Pitcher Partners. His roles with Pitcher Partners included leading the corporate finance practice group, senior audit partner and leading the corporate governance and board advisory practice area. He is a director of Navalo Financial Services Group Limited, Hypersonix Launch Systems Limited, and the not-for-profit Anglicare Victoria.

Mr van Dievoet has significant experience in investment banking, specialising in M&A. In this capacity he has worked for leading financial institutions, including the Merchant bank of IndoSuez in Belgium, ABN-AMRO, Bank BNP Group, and as executive-director for MeesPierson. Over the years he has provided strategic support on corporate growth, structuring and buy-build approaches, and assisted companies listing on the Brussels and Amsterdam Stock Exchanges (EuroNext).

Dr Pearl Grimes is a globally recognised dermatologist and a leading international authority on vitiligo and pigmentation disorders. She is the Founder and Director of the Vitiligo and Pigmentation Institute of Southern California where she treats patients from all over the world. Dr Grimes is also the director of the

Grimes Institute for Medical and Aesthetic Dermatology, where she expertly treats a wide range of dermatologic health and aesthetic concerns in patients of all ethnicities and skin types. Dr Grimes also serves as a Clinical Professor of Dermatology at the David Geffen School of Medicine at UCLA and Chief Dermatologist for Versicolor Technologies.

*“Mr Pringle, Mr van Dievoet and Dr Grimes are experienced and highly respected directors and will help maintain the depth and breadth of experience on the Board,” Prof Rosenfeld said.*

## Board Committee changes

Mr Pringle has been appointed to replace Mrs Shanahan as Chair of the Audit & Risk Committee. Further changes to the Committee memberships are expected as part of the Board renewal process.

– END –

### About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL’s lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to <https://www.clinuvel.com>.

**Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.**

### Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

### Investor Enquiries

<https://www.clinuvel.com/investors/contact-us>

### Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg), PRÉNUMBRA® or NEURACTHEL®; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, Israel, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, PRÉNUMBRA® or NEURACTHEL® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2024 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

### Contact:

Tel: +61 3 9660 4900

Fax: +61 3 9660 4909

Email: [mail@clinuvel.com](mailto:mail@clinuvel.com)

**Australia (Head Office)**, Level 22, 535 Bourke Street, Melbourne, Victoria, 3000, Australia

